Developing New Medicines Through Artificial Intelligence
On September 30, 2012, a computer program named “AlexNet” won an international competition and ushered in a new age of artificial intelligence (AI)....
On September 30, 2012, a computer program named “AlexNet” won an international competition and ushered in a new age of artificial intelligence (AI)....
While many biopharmaceutical companies are built to fulfil a need, Resilience was built to serve innovation. Founded during the COVID-19 pandemic in...
What impact can partnerships have in cell therapy commercialization success? Eytan Abraham at Resilience discusses the need for a modernized...
Consider our top 5 FAQs when it comes to MCBs Master cell banks (MCBs) are a critical starting material that lay the foundation for the scale-up and...
A Q&A with Aaron Larsen Aaron Larsen is the Technical Head for the Nucleic Acids Franchise with Resilience. He began working with nucleic acids back...
While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1,000 ongoing clinical trials and...